|
🐜
|
Systemic administration of PRO051 in Duchenne's muscular dystrophy.
19 auth.
N. Goemans,
M. Tulinius,
J. T. V. D. van den Akker,
B. Burm,
P. Ekhart,
N. Heuvelmans,
T. Holling,
A. Janson,
G. Platenburg,
J. Sipkens,
...
J. Sitsen,
Annemieke Aartsma-Rus,
G. van Ommen,
G. Buyse,
N. Darín,
J. Verschuuren,
G. Campion,
S. D. de Kimpe,
J. V. van Deutekom
|
9 |
2011 |
9
🐜
|
|
🐜
|
Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2
30 auth.
R. Lemmers,
R. Tawil,
Lisa M. Petek,
J. Balog,
Gregory J. Block,
G. Santen,
Amanda M. Amell,
Patrick J van der Vliet,
R. Almomani,
K. Straasheijm,
Y. Krom,
R. Klooster,
Yu Sun,
J. D. den Dunnen,
Q. Helmer,
...
C. Donlin-Smith,
G. Padberg,
B. V. van Engelen,
Jessica C. de Greef,
Annemieke Aartsma-Rus,
R. Frants,
M. de Visser,
C. Desnuelle,
S. Sacconi,
G. Filippova,
B. Bakker,
M. Bamshad,
S. Tapscott,
Daniel G. Miller,
S. M. van der Maarel
|
9 |
2012 |
9
🐜
|
|
🦁
|
Theoretic applicability of antisense‐mediated exon skipping for Duchenne muscular dystrophy mutations
7 auth.
Annemieke Aartsma-Rus,
I. Fokkema,
J. Verschuuren,
I. Ginjaar,
J. V. van Deutekom,
G. van Ommen,
...
J. D. den Dunnen
|
9 |
2009 |
9
🦁
|
|
🦁
|
The importance of genetic diagnosis for Duchenne muscular dystrophy
Annemieke Aartsma-Rus,
I. Ginjaar,
K. Bushby
|
8 |
2016 |
8
🦁
|
|
🐜
|
Delivery of oligonucleotide‐based therapeutics: challenges and opportunities
22 auth.
S. Hammond,
Annemieke Aartsma-Rus,
S. Alves,
S. Borgos,
R. Buijsen,
R. Collin,
Giuseppina Covello,
M. Denti,
L. Desviat,
L. Echevarría,
...
C. Foged,
G. Gaina,
A. Garanto,
A. Goyenvalle,
Magdalena Guzowska,
I. Holodnuka,
David R Jones,
S. Krause,
Taavi Lehto,
Marisol Montolio,
W. V. van Roon-Mom,
V. Arechavala-Gomeza
|
7 |
2021 |
7
🐜
|
|
🦁
|
Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense.
7 auth.
Annemieke Aartsma-Rus,
A. Janson,
W. Kaman,
M. Bremmer-Bout,
G. van Ommen,
J. D. den Dunnen,
...
J. V. van Deutekom
|
7 |
2004 |
7
🦁
|
|
🐜
|
Current status of pharmaceutical and genetic therapeutic approaches to treat DMD.
11 auth.
Christophe Pichavant,
Annemieke Aartsma-Rus,
P. Clemens,
K. Davies,
G. Dickson,
S. Takeda,
...
S. Wilton,
J. Wolff,
C. Wooddell,
Xiao Xiao,
J. Tremblay
|
7 |
2011 |
7
🐜
|
|
🦁
|
Assessing functional performance in the mdx mouse model.
Annemieke Aartsma-Rus,
M. van Putten
|
7 |
2014 |
7
🦁
|
|
🐜
|
Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle.
11 auth.
V. Arechavala-Gomeza,
I. Graham,
L. Popplewell,
A. Adams,
Annemieke Aartsma-Rus,
M. Kinali,
...
J. Morgan,
J. V. Deutekom,
S. Wilton,
G. Dickson,
Francesco Muntoni
|
7 |
2007 |
7
🐜
|
|
🦁
|
Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells
7 auth.
Annemieke Aartsma-Rus,
Wendy E. Kaman,
M. Bremmer-Bout,
Anneke A.M. Janson,
J. T. Dunnen,
G. V. Ommen,
...
J. V. Deutekom
|
7 |
2004 |
7
🦁
|
|
🦁
|
Functional analysis of 114 exon-internal AONs for targeted DMD exon skipping: indication for steric hindrance of SR protein binding sites.
7 auth.
Annemieke Aartsma-Rus,
C. D. de Winter,
A. Janson,
W. Kaman,
G. van Ommen,
J. D. den Dunnen,
...
J. V. van Deutekom
|
7 |
2005 |
7
🦁
|
